Thalassemia

Overview

Thalassemia is a hereditary blood disorder that can cause anemia because the body cannot produce enough healthy red blood cells and hemoglobin.

The typical presentation is anemia, and in severe cases, growth delay and delayed puberty may occur, or problems may arise in the spleen, liver, heart, and bones.

How the Disease Works

The main cause is a mutation in the genes that produce alpha or beta globin, and symptoms and severity can vary depending on the type and combination of mutations inherited from parents.

When globin production decreases, hemoglobin synthesis becomes insufficient, and red blood cells may fail to mature properly or be destroyed prematurely, which can lead to a decrease in oxygen transported to tissues.

Presentation Varies by Individual

Family history and genetic background are important, and it is more commonly reported in some Mediterranean, Middle Eastern, South Asian, and African-descendant populations, but individual risk and severity may vary.

The broad framework for diagnosis and management

Some individuals may have mild or almost no symptoms, but severe forms can manifest as severe anemia in early childhood, potentially affecting growth and the health of various organs.

Diagnosis involves reviewing medical and family history and performing a complete blood count (CBC), peripheral blood smear, and hemoglobin analysis, and if necessary, making a determination by synthesizing genetic test results.

Current status of treatment

It must be differentiated from other microcytic anemias, including iron deficiency anemia, and recent blood transfusions and the timing of testing can affect the interpretation of hemoglobin analysis results.

Management is carried out by monitoring blood status and organ complications according to the severity of the disease and the need for transfusions, and by administering transfusions and treatments to reduce iron overload in the body when necessary.

Mild cases may not require treatment, but in severe cases, transfusion and iron chelation therapy are important, and hematopoietic stem cell transplantation may be considered for some patients.

How to interpret clinical trials

In follow-up observations, anemia and iron accumulation as well as cardiac, hepatic, and endocrine functions and growth status are checked according to individual risk; one must not judge treatment efficacy or whether it is standard care based solely on the fact of clinical trial registration or completion.

Key points to verify in clinical consultations

In clinical practice, it is important to confirm the expected disease type and severity, family history, transfusion experience, iron overload assessment, treatment goals, and follow-up plans with the medical staff.